View Future GrowthActive Fine Chemicals 過去の業績過去 基準チェック /06Active Fine Chemicalsの過去数年間の業績に関するデータが不十分です。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 業界の成長11.00%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報31 Mar 2023最近の業績更新お知らせ • May 23Active Fine Chemicals Limited to Report Q3, 2024 Results on May 25, 2023Active Fine Chemicals Limited announced that they will report Q3, 2024 results on May 25, 2023Reported Earnings • Feb 08Second quarter 2023 earnings released: ৳0.01 loss per share (vs ৳0.059 loss in 2Q 2022)Second quarter 2023 results: ৳0.01 loss per share (improved from ৳0.059 loss in 2Q 2022). Revenue: ৳242.8m (down 31% from 2Q 2022). Net loss: ৳3.52m (loss narrowed 75% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.Reported Earnings • Dec 17Full year 2022 earnings released: EPS: ৳0.11 (vs ৳0.16 in FY 2021)Full year 2022 results: EPS: ৳0.11 (down from ৳0.16 in FY 2021). Revenue: ৳1.67b (down 8.2% from FY 2021). Net income: ৳25.9m (down 32% from FY 2021). Profit margin: 1.5% (down from 2.1% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.04 (vs ৳0.024 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.04 (up from ৳0.024 in 3Q 2021). Revenue: ৳381.6m (down 25% from 3Q 2021). Net income: ৳9.67m (up 65% from 3Q 2021). Profit margin: 2.5% (up from 1.1% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 06Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: ৳0.059 loss per share (down from ৳0.12 profit in 2Q 2021). Revenue: ৳350.8m (down 6.8% from 2Q 2021). Net loss: ৳14.1m (down 150% from profit in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.Reported Earnings • Dec 04Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: ৳0.16 (up from ৳0.23 loss in FY 2020). Revenue: ৳1.82b (up 39% from FY 2020). Net income: ৳38.3m (up ৳94.3m from FY 2020). Profit margin: 2.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.すべての更新を表示Recent updatesNew Risk • Jun 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (৳1.78b market cap, or US$14.5m).Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Md. Hossain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • May 28New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Revenue has declined by 20% over the past year. Minor Risk Market cap is less than US$100m (৳3.77b market cap, or US$32.1m).New Risk • Mar 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Bangladeshi stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 59% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (৳4.63b market cap, or US$42.2m).New Risk • Dec 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Earnings have declined by 59% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (৳4.63b market cap, or US$42.2m).Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Md. Hossain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 23Active Fine Chemicals Limited to Report Q3, 2024 Results on May 25, 2023Active Fine Chemicals Limited announced that they will report Q3, 2024 results on May 25, 2023Reported Earnings • Feb 08Second quarter 2023 earnings released: ৳0.01 loss per share (vs ৳0.059 loss in 2Q 2022)Second quarter 2023 results: ৳0.01 loss per share (improved from ৳0.059 loss in 2Q 2022). Revenue: ৳242.8m (down 31% from 2Q 2022). Net loss: ৳3.52m (loss narrowed 75% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.Reported Earnings • Dec 17Full year 2022 earnings released: EPS: ৳0.11 (vs ৳0.16 in FY 2021)Full year 2022 results: EPS: ৳0.11 (down from ৳0.16 in FY 2021). Revenue: ৳1.67b (down 8.2% from FY 2021). Net income: ৳25.9m (down 32% from FY 2021). Profit margin: 1.5% (down from 2.1% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.Upcoming Dividend • Nov 16Upcoming dividend of ৳0.025 per shareEligible shareholders must have bought the stock before 20 November 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).お知らせ • Nov 01Active Fine Chemicals Limited Has Recommends Cash Dividend for the Year Ended on June 30, 2022The Board of Directors of Active Fine Chemicals Limited has recommended 0.25% Cash dividend (other than Sponsors and Directors) for the year ended on June 30, 2022.Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.04 (vs ৳0.024 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.04 (up from ৳0.024 in 3Q 2021). Revenue: ৳381.6m (down 25% from 3Q 2021). Net income: ৳9.67m (up 65% from 3Q 2021). Profit margin: 2.5% (up from 1.1% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 06Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: ৳0.059 loss per share (down from ৳0.12 profit in 2Q 2021). Revenue: ৳350.8m (down 6.8% from 2Q 2021). Net loss: ৳14.1m (down 150% from profit in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.Valuation Update With 7 Day Price Move • Jan 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳30.00, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 4.7% over the past three years.Reported Earnings • Dec 04Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: ৳0.16 (up from ৳0.23 loss in FY 2020). Revenue: ৳1.82b (up 39% from FY 2020). Net income: ৳38.3m (up ৳94.3m from FY 2020). Profit margin: 2.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.Upcoming Dividend • Nov 22Upcoming dividend of ৳0.05 per shareEligible shareholders must have bought the stock before 29 November 2021. Payment date: 23 January 2022. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (2.9%). Lower than average of industry peers (1.7%).Reported Earnings • Jun 24Third quarter 2021 earnings released: EPS ৳0.024 (vs ৳0.19 in 3Q 2020)The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ৳510.4m (up 55% from 3Q 2020). Net income: ৳5.86m (down 87% from 3Q 2020). Profit margin: 1.1% (down from 14% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Dec 28New 90-day high: ৳16.90The company is up 1.0% from its price of ৳16.80 on 29 September 2020. The Bangladeshi market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.Is New 90 Day High Low • Oct 30New 90-day low: ৳13.90The company is down 1.0% from its price of ৳14.00 on 30 July 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period.収支内訳Active Fine Chemicals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DSE:ACTIVEFINE 収益、費用、利益 ( )BDT Millions日付収益収益G+A経費研究開発費31 Mar 231,352-5166031 Dec 221,4431179030 Sep 221,523-25191030 Jun 221,67226261031 Mar 221,69955293031 Dec 211,82853305030 Sep 211,85394305030 Jun 211,82138247031 Mar 211,383-245207031 Dec 201,201-206198030 Sep 201,206-157194030 Jun 201,308-56195031 Mar 201,776377215031 Dec 192,115541223030 Sep 192,346671226030 Jun 192,419712228031 Mar 192,308989216031 Dec 182,224915207030 Sep 182,173846207030 Jun 182,156825200031 Mar 182,272548201031 Dec 172,225556194030 Sep 172,179558181030 Jun 172,129554170031 Mar 171,896486141031 Dec 161,837459131030 Sep 161,810457125030 Jun 161,894481133030 Sep 151,6654571050質の高い収益: ACTIVEFINEが 高品質の収益 を有しているかどうかを判断するにはデータが不十分です。利益率の向上: ACTIVEFINEの 利益率 が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ACTIVEFINEの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: ACTIVEFINEの過去 1 年間の収益成長を 5 年間の平均と比較するにはデータが不十分です。収益対業界: ACTIVEFINEの過去 1 年間の収益成長がPharmaceuticals業界平均を上回ったかどうかを判断するにはデータが不十分です。株主資本利益率高いROE: ACTIVEFINEは現在利益が出ていないため、自己資本利益率 ( 0% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/30 17:16終値2026/07/30 00:00収益2023/03/31年間収益2022/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Active Fine Chemicals Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 23Active Fine Chemicals Limited to Report Q3, 2024 Results on May 25, 2023Active Fine Chemicals Limited announced that they will report Q3, 2024 results on May 25, 2023
Reported Earnings • Feb 08Second quarter 2023 earnings released: ৳0.01 loss per share (vs ৳0.059 loss in 2Q 2022)Second quarter 2023 results: ৳0.01 loss per share (improved from ৳0.059 loss in 2Q 2022). Revenue: ৳242.8m (down 31% from 2Q 2022). Net loss: ৳3.52m (loss narrowed 75% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
Reported Earnings • Dec 17Full year 2022 earnings released: EPS: ৳0.11 (vs ৳0.16 in FY 2021)Full year 2022 results: EPS: ৳0.11 (down from ৳0.16 in FY 2021). Revenue: ৳1.67b (down 8.2% from FY 2021). Net income: ৳25.9m (down 32% from FY 2021). Profit margin: 1.5% (down from 2.1% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.
Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.04 (vs ৳0.024 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.04 (up from ৳0.024 in 3Q 2021). Revenue: ৳381.6m (down 25% from 3Q 2021). Net income: ৳9.67m (up 65% from 3Q 2021). Profit margin: 2.5% (up from 1.1% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 06Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: ৳0.059 loss per share (down from ৳0.12 profit in 2Q 2021). Revenue: ৳350.8m (down 6.8% from 2Q 2021). Net loss: ৳14.1m (down 150% from profit in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.
Reported Earnings • Dec 04Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: ৳0.16 (up from ৳0.23 loss in FY 2020). Revenue: ৳1.82b (up 39% from FY 2020). Net income: ৳38.3m (up ৳94.3m from FY 2020). Profit margin: 2.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
New Risk • Jun 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (৳1.78b market cap, or US$14.5m).
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Md. Hossain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • May 28New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Revenue has declined by 20% over the past year. Minor Risk Market cap is less than US$100m (৳3.77b market cap, or US$32.1m).
New Risk • Mar 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Bangladeshi stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 59% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (৳4.63b market cap, or US$42.2m).
New Risk • Dec 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.6x net interest cover). Earnings have declined by 59% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (৳4.63b market cap, or US$42.2m).
Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Md. Hossain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 23Active Fine Chemicals Limited to Report Q3, 2024 Results on May 25, 2023Active Fine Chemicals Limited announced that they will report Q3, 2024 results on May 25, 2023
Reported Earnings • Feb 08Second quarter 2023 earnings released: ৳0.01 loss per share (vs ৳0.059 loss in 2Q 2022)Second quarter 2023 results: ৳0.01 loss per share (improved from ৳0.059 loss in 2Q 2022). Revenue: ৳242.8m (down 31% from 2Q 2022). Net loss: ৳3.52m (loss narrowed 75% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
Reported Earnings • Dec 17Full year 2022 earnings released: EPS: ৳0.11 (vs ৳0.16 in FY 2021)Full year 2022 results: EPS: ৳0.11 (down from ৳0.16 in FY 2021). Revenue: ৳1.67b (down 8.2% from FY 2021). Net income: ৳25.9m (down 32% from FY 2021). Profit margin: 1.5% (down from 2.1% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • Nov 16Upcoming dividend of ৳0.025 per shareEligible shareholders must have bought the stock before 20 November 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 22% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).
お知らせ • Nov 01Active Fine Chemicals Limited Has Recommends Cash Dividend for the Year Ended on June 30, 2022The Board of Directors of Active Fine Chemicals Limited has recommended 0.25% Cash dividend (other than Sponsors and Directors) for the year ended on June 30, 2022.
Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.04 (vs ৳0.024 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.04 (up from ৳0.024 in 3Q 2021). Revenue: ৳381.6m (down 25% from 3Q 2021). Net income: ৳9.67m (up 65% from 3Q 2021). Profit margin: 2.5% (up from 1.1% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 06Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: ৳0.059 loss per share (down from ৳0.12 profit in 2Q 2021). Revenue: ৳350.8m (down 6.8% from 2Q 2021). Net loss: ৳14.1m (down 150% from profit in 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.
Valuation Update With 7 Day Price Move • Jan 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳30.00, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 4.7% over the past three years.
Reported Earnings • Dec 04Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: ৳0.16 (up from ৳0.23 loss in FY 2020). Revenue: ৳1.82b (up 39% from FY 2020). Net income: ৳38.3m (up ৳94.3m from FY 2020). Profit margin: 2.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
Upcoming Dividend • Nov 22Upcoming dividend of ৳0.05 per shareEligible shareholders must have bought the stock before 29 November 2021. Payment date: 23 January 2022. Trailing yield: 0.2%. Lower than top quartile of Bangladeshi dividend payers (2.9%). Lower than average of industry peers (1.7%).
Reported Earnings • Jun 24Third quarter 2021 earnings released: EPS ৳0.024 (vs ৳0.19 in 3Q 2020)The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ৳510.4m (up 55% from 3Q 2020). Net income: ৳5.86m (down 87% from 3Q 2020). Profit margin: 1.1% (down from 14% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Dec 28New 90-day high: ৳16.90The company is up 1.0% from its price of ৳16.80 on 29 September 2020. The Bangladeshi market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Oct 30New 90-day low: ৳13.90The company is down 1.0% from its price of ৳14.00 on 30 July 2020. The Bangladeshi market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period.